PDCD1 and metastatic melanoma: Previous studies showed that high CD16 expression, as well as intertumoral CD16+ macrophages levels, are associated with immune-rich tumors and subsequent better prognosis in metastatic melanoma patients treated with anti-PD-1 monotherapy, or in combination with anti-CTLA-4 [48].